Syncom Formulations (India) Limited Share Price & Company Info
- Market cap
- ₹1,809 Cras reported by NSE
- 52-week high
- ₹27.4930-SEP-2026
- 52-week low
- ₹10.2130-MAR-2026
- P/E (NSE)
- 21.15sector P/E 21.14
- Face value
- ₹1.00
- Shares issued
- 94,00,00,000
- Volume
- 3,99,48,940₹87.04 Cr traded
- Delivery
- 20.77%of traded quantity
- Price band
- 20%₹16.33 – ₹24.49 on 2026-11-02
- Annual volatility
- 60.75%NSE, from daily returns
- Series
- EQrolling settlement
- BSE group
- Bscrip code 524470
- ISIN
- INE312C01025
- Listed on NSE
- 18-Nov-2022
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited is listed on the National Stock Exchange of India under the symbol SYNCOMF in the EQ series. NSE classifies it under the basic industry Pharmaceuticals, part of the Healthcare sector. Its shares were listed on NSE on 18-Nov-2022. Each share has a face value of ₹1.00.
In the end-of-day data for 16 November 2026 the stock closed at ₹21.19, up 4.44% on the day. NSE puts the company's market capitalisation at about ₹1,809 crore. Over the past 52 weeks it has traded between ₹10.21 and ₹27.49, so the last price is 107.5% above the low and 22.9% below the high.
3,99,48,940 shares changed hands that day, and 20.77% of them were taken as delivery rather than squared off intraday. A high delivery share means most of the day's buyers chose to hold the shares; a low one usually means the volume was mostly short-term trading.
EQ is the normal equity series: shares settle on the usual T+1 cycle and intraday trading is allowed.
NSE currently lists a regulatory note for this stock: “High low price var. was greater than 75% in prev. 3 mths. | High low price var. was greater than 100% in prev. 6 mths. | High low price var. was greater than 150% in prev. 12 mths”. Notes like these come from the exchange's surveillance and disclosure checks and can mean higher margins, trade-for-trade settlement or limits on trading. Check the NSE quote page for the current position before trading.
NSE puts the stock's annualised volatility at 60.75%. That is very high: moves of several percent in a single day are routine.
Because the share trades below ₹30, it also appears in our list of penny stocks under ₹30, which explains the extra risks that come with low-priced shares.
Syncom Formulations (India) Limited quarterly results
In the quarter ended June 2026 (un-audited), Syncom Formulations (India) Limited reported total income of ₹132 crore and a net profit of ₹24.59 crore, or ₹0.26 per share. That is a net margin of 18.6% on income.
A year earlier, in the June 2025 quarter, income was ₹123 crore with a net profit of ₹15.73 crore. Income has grown 8.1% year on year. Net profit has risen 56.3%.
Syncom Formulations (India) Limited was profitable in 5 of the 5 quarters shown below, every one of them. Figures are as filed with NSE, in ₹ crore.
| Quarter ended | Total income | Profit before tax | Net profit | EPS | Status |
|---|---|---|---|---|---|
| June 2026 | 132 | 31.91 | 24.59 | 0.26 | Un-Audited |
| March 2026 | 148 | 32.86 | 24.57 | 0.26 | Audited |
| December 2025 | 120 | 25.05 | 18.86 | 0.23 | Un-Audited |
| September 2025 | 127 | 22.36 | 16.84 | 0.18 | Un-Audited |
| June 2025 | 123 | 20.26 | 15.73 | 0.21 | Un-Audited |
Syncom Formulations (India) Limited shareholding pattern
At the end of September 2026, promoters and the promoter group held 50.57% of Syncom Formulations (India) Limited, with the public holding 49.43%. The promoter stake has not changed across the 8 quarterly filings shown, from December 2024 to September 2026.
| Quarter ended | Promoter & Promoter Group (%) | Public (%) |
|---|---|---|
| September 2026 | 50.57 | 49.43 |
| June 2026 | 50.57 | 49.43 |
| March 2026 | 50.57 | 49.43 |
| December 2025 | 50.57 | 49.43 |
| September 2025 | 50.57 | 49.43 |
| June 2025 | 50.57 | 49.43 |
| March 2025 | 50.57 | 49.43 |
| December 2024 | 50.57 | 49.43 |
Syncom Formulations (India) Limited share price performance
Over the past year the Syncom Formulations (India) Limited share price has gained 15.85%, against a fall of 10.92% for the NIFTY 50, so it has outperformed that index by 26.77 percentage points.
Across the 6 periods in the table, the stock beat the NIFTY 50 in 5. Past returns describe what happened; they do not predict what comes next.
| Period | SYNCOMF | NIFTY 50 |
|---|---|---|
| 1 month | -23.05% | +1.91% |
| 3 months | +48.35% | -5.20% |
| 6 months | +40.47% | -3.94% |
| 1 year | +15.85% | -10.92% |
| 2 years | -2.72% | -5.29% |
| 3 years | +128.40% | +20.44% |
Syncom Formulations (India) Limited vs industry peers
NSE compares Syncom Formulations (India) Limited with 6 other listed companies in Pharmaceuticals. By market capitalisation it ranks 4 of 7.
Its P/E of 21.14 compares with a median of 27.25 for the other companies in the group.
| Company | Market cap | Price (₹) | P/E | Promoter % | Qtr income | Qtr net profit |
|---|---|---|---|---|---|---|
| HESTERBIO | 1,964 | 2,309.00 | 36.39 | 53.73 | 74.34 | 14.71 |
| INDOCO | 1,938 | 210.00 | — | 58.86 | 413 | 82.32 |
| PANACEABIO | 1,906 | 311.10 | — | 72.48 | 141 | 1.39 |
| SYNCOMF | 1,814 | 19.30 | 21.14 | 50.57 | 132 | 24.59 |
| WINDLAS | 1,789 | 867.00 | 27.21 | 63.31 | 253 | 17.65 |
| VENUSREM | 1,644 | 1,230.00 | 13.61 | 41.76 | 181 | 25.53 |
| NGLFINE | 1,567 | 2,536.90 | 27.28 | 72.49 | 144 | 16.45 |
Syncom Formulations (India) Limited announcements, board meetings and corporate actions
Latest announcements
The most recent filings Syncom Formulations (India) Limited has made with NSE, newest first:
- 08-Oct-2026 · Certificate under SEBI (Depositories and Participants) Regulations, 2018: Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 (PDF)
- 01-Oct-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
- 01-Oct-2026 · Change in Management: Syncom Formulations (India) Limited has informed the Exchange about change in Management (PDF)
- 01-Oct-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
- 01-Oct-2026 · Shareholders meeting: Syncom Formulations (India) Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results. (PDF)
- 01-Oct-2026 · Shareholders meeting: Syncom Formulations (India) Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026 (PDF)
- 30-Sep-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
- 26-Sep-2026 · General Updates: Syncom Formulations (India) Limited has informed the Exchange about General Updates (PDF)
Board meetings
- 11-Aug-2026 · Financial Results/Dividend/Other business matters: To consider and approve the financial results for the period ended Jun 30, 2026, dividend and other business matters
- 22-May-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended March 31, 2026 and other business matters
- 12-Feb-2026 · Financial Results/Other business matters: To consider and approve the financial results for the period ended December 31, 2025 and other business matters
- 12-Nov-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended September 30, 2025 and other business matters
- 08-Aug-2025 · Financial Results/Other business matters: To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters
Corporate actions
The corporate actions on record include 1 dividend. The ex-date is the first day the shares trade without the entitlement.
- Dividend - Re 0.10 Per Share · ex-date 23-Sep-2026 · record date 23-Sep-2026
- Annual General Meeting · ex-date 23-Sep-2024 · book closure 24-Sep-2024 to 30-Sep-2024
- Annual General Meeting · ex-date 18-Sep-2023 · book closure 20-Sep-2023 to 26-Sep-2023
Risk notice: low-priced and small-company shares can be illiquid, volatile and subject to manipulation, and shareholders can lose their entire investment. This page is a factual summary, not a recommendation to buy or sell Syncom Formulations (India) Limited.
Where to find Syncom Formulations (India) Limited's financials
Direct downloads from NSE:
- Annual report 2025-26 (PDF, 4.47 MB)
- Annual report 2024-25 (PDF, 17.23 MB)
- Annual report 2023-24 (PDF)
- Annual report 2022-23 (ZIP)
- Business responsibility and sustainability report (BRSR) 2025-26
- Business responsibility and sustainability report (BRSR) 2024-25
- Business responsibility and sustainability report (BRSR) 2023-24
For full financial statements, shareholding detail and every company announcement, go to the source:
- NSE quote pageOfficial price, price band, surveillance status, shareholding pattern and corporate actions.
- Annual reports (NSE)Search “SYNCOMF” to download Syncom Formulations (India) Limited's annual reports as filed with the exchange.
- Announcements and results (NSE)Search “SYNCOMF” for quarterly results, board meetings and other company filings.
- BSE quote page (524470)BSE price, filings, results and shareholding for the same company.
- ScreenerTen years of profit and loss, balance sheet, cash flow and key ratios.
- TradingView chartInteractive price chart with technical indicators.
- Google FinanceQuick price overview and recent news coverage.
- Yahoo FinanceHistorical prices you can download, plus summary statistics.
Other Pharmaceuticals stocks on MCX Trends
- Anlon Healthcare Limited (AHCL · ₹25.77)
- Sigachi Industries Limited (SIGACHI · ₹28.16)
- Vineet Laboratories Limited (VINEETLAB · ₹37.52)
- Ambalal Sarabhai Enterprises Limited (AMBALALSA · ₹38.62)
- Medico Remedies Limited (MEDICO · ₹18.31)
- Nectar Lifesciences Limited (NECLIFE · ₹10.31)
- Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM · ₹30.67)
- Mangalam Drugs And Organics Limited (MANGALAM · ₹28.60)
Frequently asked questions
What is the Syncom Formulations (India) Limited share price?
Syncom Formulations (India) Limited (NSE: SYNCOMF) closed at ₹21.19 in the end-of-day data for 16 November 2026. For a live price, use the NSE quote page or your broker, because this page is updated from end-of-day files.
Which sector does Syncom Formulations (India) Limited belong to?
NSE classifies Syncom Formulations (India) Limited under Pharmaceuticals, in the Healthcare sector.
What is the 52-week high and low of SYNCOMF?
The 52-week high is ₹27.49 (30-SEP-2026) and the 52-week low is ₹10.21 (30-MAR-2026), according to NSE.
Is Syncom Formulations (India) Limited a penny stock?
At ₹21.19 the share trades below ₹30, so it appears on our list of penny stocks under ₹30. A low share price on its own says nothing about whether a company is cheap or expensive; market capitalisation, debt, profits and exchange surveillance status matter far more.
What is the promoter holding in Syncom Formulations (India) Limited?
Promoters and the promoter group held 50.57% of Syncom Formulations (India) Limited at the end of September 2026, according to the shareholding pattern filed with NSE.
What were Syncom Formulations (India) Limited's latest quarterly results?
For the quarter ended June 2026, Syncom Formulations (India) Limited reported total income of ₹132 crore and a net profit of ₹24.59 crore (EPS ₹0.26).
Where can I find Syncom Formulations (India) Limited's annual report and financial results?
Annual reports, quarterly results and other filings are published on the NSE corporate filings pages (search for SYNCOMF) and on BSE. Screener also lays out several years of financial statements in one place. Links to all of these are above.